A comprehensive profile of recurrent glioblastoma (Q38797345)

6 September 2017

title

A comprehensive profile of recurrent glioblastoma (English)

1 reference

6 September 2017

B Campos

1

1 reference

6 September 2017

L R Olsen

series ordinal

2

1 reference

6 September 2017

T Urup

series ordinal

3

1 reference

6 September 2017

H S Poulsen

series ordinal

4

1 reference

6 September 2017

language of work or name

English

0 references

publication date

4 April 2016

1 reference

6 September 2017

1 reference

6 September 2017

volume

35

1 reference

6 September 2017

issue

45

1 reference

6 September 2017

page(s)

5819-5825

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2016.85

6 September 2017

exact match

0 references

cites work

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Standards of care for treatment of recurrent glioblastoma--are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Spatiotemporal Evolution of the Primary Glioblastoma Genome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Interaction of hypoxia-inducible factor-1α and Notch signaling regulates medulloblastoma precursor proliferation and fate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

The somatic genomic landscape of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

The influence of surgery on recurrence pattern of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Genetic profiling of a distant second glioblastoma multiforme after radiotherapy: Recurrence or second primary tumor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Second primary glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Different molecular patterns in glioblastoma multiforme subtypes upon recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

EXPANDS: expanding ploidy and allele frequency on nested subpopulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Identification of human brain tumour initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Marker-independent method for isolating slow-dividing cancer stem cells in human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Evidence for label-retaining tumour-initiating cells in human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Aberrant self-renewal and quiescence contribute to the aggressiveness of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

A restricted cell population propagates glioblastoma growth after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Insight into the complex regulation of CD133 in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Stem cell marker CD133 affects clinical outcome in glioma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Immediate post-operative MRI suggestive of the site and timing of glioblastoma recurrence after gross total resection: a retrospective longitudinal preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Molecular analysis of a recurrent glioblastoma treated with bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by Glioma stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Independent molecular development of metachronous glioblastomas with extended intervening recurrence-free interval.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

A novel stem cell culture model of recurrent glioblastoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.85

Antigen variation in a human glioblastoma: from the primary tumor to the second recurrence, permanent cell line and xenotransplantation tumors

31 March 2020

1 reference

12 December 2020

Pathological spectrum in recurrences of glioblastoma multiforme

1 reference

12 December 2020

Residual tumor cells are unique cellular targets in glioblastoma

1 reference

12 December 2020

Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma.

1 reference

12 December 2020

Identifiers

DOI

10.1038/ONC.2016.85

1 reference

Dimensions Publication ID

6 September 2017

1046753695

0 references

1 reference